# US 2013/0156766 A1 · Treatment of dry age related macular degeneration

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0156766 A1
- Document ID: US20130156766A1
- Status: Published application
- Kind: A1
- Application number: 13/677,646
- Filed: 2012-11-15
- Published: 2013-06-20
- Earliest claimed: 2011-11-15
- Assignees: Allergan, Inc.
- Inventors: Jyotirmoy X. Kusari; Yanbin Liang; Larry A. Wheeler
- Web page: https://patentgrep.com/patent/US20130156766A1

## CPC

- A61K 39/0005: {Vertebrate antigens (from snakes A61K39/38)}
- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61P 27/02: Ophthalmic agents
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A method of treating dry age related macular degeneration (“AMD”) comprising administration to the eye of an individual in need thereof of a therapeutically effective amount of an anti-endoglin agent.

## Claims

### Claim 1

A method of treating dry age related macular degeneration (“AMD”) comprising administration to the eye of an individual in need thereof of a therapeutically effective amount of an anti-endoglin agent.

### Claim 2 (depends on 1)

The method of claim 1, wherein the anti-endoglin agent is an antibody or fragment thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein the anti-endoglin agent is an anticalin.

### Claim 4 (depends on 1)

The method of claim 1, wherein the anti-endoglin agent is an ankyrin repeat.

### Claim 5 (depends on 1)

The method of claim 1, wherein the anti-endoglin agent is an avimer.

### Claim 6 (depends on 1)

The method of claim 1, wherein the anti-endoglin agent is a nanobody.

### Claim 7 (depends on 1)

The method of claim 1, wherein the anti-endoglin agent is a versabody.
